Corvus Pharmaceuticals, Inc. (FRA:C17)

Market Cap	1.46B +375.0%
Revenue (ttm)	n/a
Net Income	-12.85M
EPS	-0.48
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	120
Average Volume	173
Open	17.04
Previous Close	16.86
Day's Range	17.04 - 17.04
52-Week Range	2.35 - 21.70
Beta	n/a
RSI	67.83
Earnings Date	Mar 24, 2026

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company’s lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ci...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 31
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: C17

Financial Performance

Financial numbers in USD